key: cord-0271731-70i5675a
authors: Lythgoe, K. A.; Golubchik, T.; Hall, M.; House, T.; MacIntyre-Cockett, G.; Fryer, H.; Thomson, L.; Nurtay, A.; Buck, D.; Green, A.; Trebes, A.; Piazza, P.; Lonie, L. J.; Studley, R.; Rourke, E.; Cook, D.; Smith, D.; Bashton, M.; Nelson, A.; Crown, M.; McCann, C.; Young, G. R.; de Santos, R. A. N.; Richards, Z.; Tariq, A.; Wellcome Sanger Institute COVID-19 Surveillance Team,; COVID-19 Infection Survey Group,; The COVID-19 Genomics UK consortium,; Fraser, C.; Diamond, I.; Barrett, J.; Walker, S.; Bonsall, D.
title: Lineage replacement and evolution captured by the United Kingdom Covid Infection Survey
date: 2022-01-06
journal: nan
DOI: 10.1101/2022.01.05.21268323
sha: 8f6ad92f39135f7c1ed18caa6888311653a0a52d
doc_id: 271731
cord_uid: 70i5675a

The Office for National Statistics COVID-19 Infection Survey is a large household-based surveillance study based in the United Kingdom. Here, we report on the epidemiological and evolutionary dynamics of SARS-CoV-2 determined by analysing sequenced samples collected up until 13th November 2021. We observed four distinct sweeps or partial-sweeps, by lineages B.1.177, B.1.1.7/Alpha, B.1.617.2/Delta, and finally AY.4.2, a sublineage of B.1.617.2, with each sweeping lineage having a distinct growth advantage compared to their predecessors. Evolution was characterised by steady rates of evolution and increasing diversity within lineages, but with step increases in divergence associated with each sweeping major lineage, leading to a faster overall rate of evolution and fluctuating levels of diversity. These observations highlight the value of viral sequencing integrated into community surveillance studies to monitor the viral epidemiology and evolution of SARS-CoV-2, and potentially other pathogens, particularly as routine PCR testing is phased out or in settings where large-scale sequencing is not feasible.

from address lists to ensure as representative a sample of the population as possible [6, 11] . RT-PCR positive samples collected during the survey were sequenced as part of the COG-UK Genomics Consortium [3] . Here, we present an analysis of the 16817 consensus sequences from RT-PCR positive samples collected between 26th April 2020 to 13th November 2021 that had genomic coverage over 50%, with the aim of reconstructing the key epidemiological and evolutionary features of the UK epidemic. These data capture the sequential sweeps and partial sweeps of the B.1.177, B.1.1.7/Alpha, and B.1.617.2/Delta, and AY.4.2 lineages which the UK experienced, plus the sporadic appearance of other VOCs and Variants Under Investigation (VUIs), most notably B.1.351/Beta and P.1/Gamma. For each of the sweeping lineages we calculated their growth rate advantage, with each lineage having a progressively higher growth rate compared to previously circulating lineages.

A feature of B.1.1.7/Alpha is the RT-PCR S-gene target failure (SGTF) caused by the Spike DH69/V70 deletion. During the UK epidemic, SGTF greatly facilitated the rapid quantification of B.1.1.7/Alpha case numbers [12] [13] [14] [15] , and subsequently non-SGTF was used to quantify B.1.617.2/Delta case numbers [16, 17] . By comparing the presence or absence of SGTF with genotype for samples in the ONS CIS, we determined the specifity of RT-PCR S-gene target failure (SGTF), for B.1.1.7/Alpha, and non-SGTF for B.1.617/Delta, with high specificity when lineage prevalences were high (~99%), but low specificity at low prevalences.

In addition to measuring the growth rate advantage of sweeping lineages, we determined how these sweeps impacted measures of the genetic diversity and divergence of the virus, both at the within-lineage and between-lineage levels. As well as VOCs, which are characterised by a large number (constellation) of mutations, single mutations can also be a cause for concern. For example, the appearance of the E484K mutation in Spike, which likely contributes to the partial immune escape [2] on the highly transmissible B.1.1.7/Alpha genetic background was rightly seen as a cause for concern [18] . We determined the number of samples in which we saw any of the Spike amino acid replacements reported to confer antigenic change to antibodies as listed by the COG-UK Mutation Explorer [2, 19] , taking particular note of those where the mutation was not lineage defining given the lineage of the sample, and therefore likely to represent recently acquired mutations. In addition, we calculated how often the ancestral nucleotide changes corresponding to these replacements appeared on the phylogenic tree of the ONS CIS samples. Most mutations were rare and sporadic, appearing in a single sample, but others were notably more common, with some having appeared independently on multiple phylogenetic lineages, suggesting convergent evolution.

Although sequences from the ONS CIS represented about 1.6% of the total number of SARS-CoV-2 sequences obtained in the UK during this period, we were able to reconstruct the key epidemiological and evolutionary aspects of the epidemic. Our observations highlight the value of incorporating sequencing into large-scale surveillance studies of infectious disease, and the important role that community-based genomic surveillance studies can have in the monitoring of infectious disease. Although the ONS CIS is based in the UK, in which sequencing effort has been unprecidented, this is of particular importance in settings where routine testing is likely to be scaled back, and for countries exploring the best strategies for tracking SARS-CoV-2 as well as other pathogens.

Between April 2020 and late December 2020, a random selection of RT-PCR samples collected as part of the ONS CIS were sequenced. There was a substantial increase in the size of the ONS CIS between August and October 2020, which went from testing under 50,000 people per fortnight to around 180,000 people per fortnight [20] , and consequently the number of sequenced samples also increased. In response to the emergence of B.1.1.7/Alpha [21] , the sequencing effort was intensified again, with the aim of prospectively sequencing all RT-PCR positive samples in addition to unsequenced earlier samples where possible. Here we report on the sequenced samples with cycle threshold (Ct) <=30 and over 50% genome coverage collected between 26th April 2020 and 13 November 2021.

The Pango lineage [22] for all the samples was determined using Pangolin v3.1.16 [23] . Since 7 December 2020 we have provided publicly available weekly reports, giving the number of sequenced samples with >50% genome coverage by lineage [24] . Observing the raw data ( Fig. 1) , we see a small 2020 autumn peak in sequenced samples, dominated by B.1.177 and its sub-lineages. We then see a decline in cases due to the second national lockdown which lasted from 5th November to 2nd December 2020, before the number of sequenced samples started to rise again. This is attributed to a relaxation of restrictions during the Christmas period and corresponded to a rapid rise in the number of B.1.1.7/Alpha infections. After the commencement of a further lockdown in England, Scotland and Northern Ireland in early January, cases declined again, before another rapid increase in the number of sequenced samples that were dominated by B.1.617.2/Delta, with this increase corresponding to a phased reopening on the 19th May and 20th June 2021.

When the proportion of samples belonging to each lineage are plotted over time (Fig. 1) , the sequential sweeps and partial sweeps of B.1.177, B.1.1.7/Alpha, and B.1.617.2/Delta, can be readily observed, followed by the slower partial sweep of the B.1.617.2 sublineage AY.4.2. The lineage dynamics observed using ONS CIS samples are broadly in line with those observed for pillar 2 (community testing) samples across the whole COG-UK consortium, but excluding the ONS CIS samples (Figs. S1, S2). However, some differences are noticeable. The first samples of each sweeping lineage were collected earlier by COG-UK, and sustained lineage growth rates were also noticeable two-to-four weeks earlier among COG-UK samples for lineages B.1.177, B.1.617.2/Delta and AY.4.2, but at a similar time to the ONS-CIS for B.1.1.7/Alpha. This reflects the much larger number of COG-UK compared to ONS-CIS sequences, but also may reflect differences in the demographics sampled. It is interesting that the lineages dynamics among the two datasets are most similar for B.1.1.7/Alpha, which most likely emerged within the UK, whereas initial growth of the other lineages was driven by importations. 

For each of the sweeping lineages in turn, we calculated the relative growth advantage compared to all other contemporary lineages using the ONS-CIS data (Fig. 2 ). In line with previous findings [25 -27] , we found that B.1.177 had a significant growth rate advantage compared to all other co-circulating SARS-CoV-2 lineages, which peaked at around 0.075 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.05.21268323 doi: medRxiv preprint per day towards the end of September 2020 before slowly declining through October 2020. In other words, B.1.177 case numbers grew about 7.5% faster each day when compared to all other cases. The B.1.177 lineage most likely originated in Spain, with the first samples collected in June 2020 [26] , and with international travel from Europe being a major driver of new infections of this lineage in the UK from August 2020 [25, 26] . However, there is continuing debate as to whether the growth advantage of B.1.177 was also associated with increased transmissibility, with some reports arguing there is little evidence for increased intrinsic transmissibility [25, 26] , whilst others suggesting importations alone cannot explain the patterns of replacement [27] . In the ONS CIS data, we observed a continued growth advantage of B.1.177 in the UK thoughout October 2020, when the number of incident B.1.177 infections was relatively high (Fig. S1 ) whilst travel to the UK from other European countries had tailed off [25, 26] , which is consistent with increased B.1.177 transmissibility.

If we consider the growth advantage of B.1.1.7/Alpha, which largely replaced B.1.177 and other circulating lineages between October 2020 and February 2021, we continue to find a pattern consistent with a transmission advantage of B.1.177 over previously circulating lineages. The early growth advantage of B.1.1.7/Alpha, when compared to other contemporaneous lineages, reached a peak of approximately 0.14 per day in November 2020, when both B.1.177 and earlier lineages were in circulation (Figs 1, S1), before settling to around 0.05 per day in December 2020, by which time almost all non-Alpha lineages were B.1.177. This is the pattern we would expect if B.1.177 has a transmission advantage compared to other (non-B.1.1.7/Alpha) lineages; B.1.1.7/Alpha will grow relatively faster in a background of B.1.177 and other less transmissible lineages, but will grow relatively slower if the background consists of only B.1.177. This declining growth rate advantage of B.1.1.7/Alpha after initial high values has also been noted in previous reports [14, [27] [28] [29] [30] .

There is little doubt, however, that an intrinsic transmission advantage of B.1.1.7/Alpha was the major force driving the rapid increase of B.1.1.7 infections [14, [27] [28] [29] [30] . Finally, by the time B.1.617.2/Delta emerged it was in a background of almost exclusively B.1.1.7/Alpha infections, making interpretation much more straightforward. We estimate that B.1.617.2/Delta had a growth advantage of around 0.12 per day compared to B.1.1.7/Alpha, in line with previous estimates [27, 31] , likely due to a combination of increased transmissibility and immune evasion [27] . More recently AY.4.2, a Delta sublineage with Y145H, a potential antibody escape mutation, is currently increasing in frequency in the UK [32, 33] . We estimate AY.4.2 and its sublineages (which in turn is a sublineage of B.1.617.2), had a growth advantage of 0.02 per day compared to all other Delta lineages, with an estimated doubling time of 28 days. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.05.21268323 doi: medRxiv preprint SGTF was a good proxy for lineage when lineage prevalence was high, but not when lineage prevalence was low SGTF was an attractive surrogate marker for B.1.1.7/Alpha in the UK since it enabled the lineage to be tracked in the population without the delays incurred due to sequencing, and enabled samples with high cycle threshold (Ct) to be included in analyses even if they couldn't be sequenced. For all samples in the analysis, we classed those as having SGTF if, during RT-PCR testing, N and ORF1ab were successfully amplified, but S was not, and non-SGTF samples as those where N, ORF1ab and S were all amplified. Since we only consider samples with Ct<=30 (and hence those with relatively high viral loads), almost all samples were classified as SGTF or non-SGTF. Lineage was generally a good indicator of SGTF, with 99.0% (3424/33460) of B. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.05.21268323 doi: medRxiv preprint Nov 2021) non-SGTF was highly specific for B.1.617.2/Delta (Fig. 3 , Table S2 ). However, when the prevalence of these variants was lower, SGTF was a poorer indicator of lineage, either due to the presence of other co-circulating lineages with or without the DH69/V70 deletion, or due to SGTF independent of the corresponding B.1.617.2/Delta lineage mutation as a result of RT-PCR technical failures or other errors. Prior to November 2020, most SGTF samples were associated with the B.1.258 lineage, and conversely, from February to April 2021, non-SGTF samples represented a broad range of lineages, including Alpha, making non-SGTF a poor indicator of any specific lineage during this period. 1.1.7/Alpha lineages, diversity was relatively low when they first appeared, and gradually increased through time (Fig. 1 ). This initial low diversity is a consequence of their relatively recent emergence in Spain and South East England, respectively, before first detection in the ONS CIS data. The slightly higher diversity in B.1.177 likely reflects its geographical spread and multiple introductions from Europe. B.1.617.2/Delta, on the other hand, had high initial diversity (Fig. 1) , with multiple introductions into the UK of this lineage from an already diverse source population in India [16] . Diversity in this lineage then declined slightly corresponding to fewer introductions as a result of travel restrictions from India, before then steadily rising again.

In contrast, when we consider overall genetic diversity, we see transient increases, peaking when two or more distinct lineages are at relatively high frequencies ( Fig. 1 ), but then . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.05.21268323 doi: medRxiv preprint declining as single lineages dominate the population. It is notable that in August 2021 overall levels of diversity were lower than in August 2020 despite much higher prevalence (e.g. in England 1.32% in the week ending 31 July 2021 vs 0.05% the week ending 25 August 2020).

As expected, divergence from the root of the phylogeny increased gradually through time, both within-lineages (Fig. S4 ) and across all lineages (Fig. 4) , demonstrating the presence of a strong molecular clock. It has been noted previously that although divergence within the B.1.1.7/Alpha lineage increased at a similar rate to previously circulating lineages, it had accumulated a disproportionate number of lineage defining mutations [21] . We also observe this pattern, with similar estimated molecular clock rates (line gradients) of 0.00038 substitutions per site per year (s/s/y) for B.1.177, and of 0.00034 s/s/y for B.1.1.7/Alpha, but with the B.1.1.7 line appearing shifted upwards (Fig. S4 ). Since many of the B.1.1.7/Alpha lineage defining mutations were nonsynonymous and in the Spike region, it has been hypothesised Alpha arose during a long-term chronic infection [21] .

Meanwhile, the data indicate a higher substitution rate for B.1.617.2/Delta (0.00064 s/s/y), again with a shift up in the regression line, possibly as a consequence of divergence within India before importation into the UK. Finally, the observed substitution rate over all ONS sequences is 0.00094 s/s/y, which is faster than any of the within-lineage rates we measured, and is largely a result of the step increases in divergence associated with the new variants. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.05.21268323 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.05.21268323 doi: medRxiv preprint

There is justified concern that, as population levels of immunity increase via vaccination and/or prior infection, SARS-CoV-2 may acquire immune escape mutations on already highly transmissible genetic backgrounds. For example, concerns were raised over the presence of E484K in some B.1.1.7/Alpha isolates in the UK [36] . More recently the AY.4.2 sublineage of Delta has Y145H, a potential antibody escape mutation. We determined the number of consensus sequences with potential antibody escape mutations for each of the four sweeping lineages in our dataset: B.1.177, B.1.1.7/Alpha, B.1.617.2/Delta and AY.4.2. We considered Spike amino acid replacements reported to confer antigenic change to antibodies as listed by the COG-UK Mutation Explorer [2, 19] , and only considered mutations which were not lineage defining on the genetic background on which they were found. For example, L18F is found in the majority of B.1.177 samples, but only a small proportion of Alpha and Delta samples, and therefore L18F was excluded on a B. 5) . By performing ancestral state reconstruction on the phylogeny of all over 95% coverage ONS CIS samples collected before 17th July 2021 (Fig. S5) we determined the number of ancestral occurances of each of these mutations (multiple ancestral nodes are depicted on Fig. 5) . Whereas most mutations have a single origin on the tree, some appear multiple times, including L18F (14 times), H146X (9 times), E484K (5 times), and S255F (6 times). Some of these mutations are lineage defining for multiple lineages, indicating convergent evolution and benefit on different genetic backgrounds. Most however, only appeared once, suggesting they may have had limited evolutionary advantage when occurring in isolation, at least during the sampling period considered. It remains possible that these mutations may have an advantage on different genetic backgrounds (epistasis) and/or in different environments, for example as acquired immunity increases due to infection or vaccination.

. CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.05.21268323 doi: medRxiv preprint The stacked bar chart indicates the number of samples in our dataset with the mutation. All antigenic mutations included in the COG-UK mutational explorer [19] , were included. For clarity, mutations on a lineage that define that lineage are not considered. The y-axis has been truncated for clarity, but L18F was observed in 77 Alpha samples.

Surveillance studies such as the ONS CIS are valuable tools for tracking the emergence and spread of infectious disease. Since participants are selected at random and are periodically tested for SARS-CoV-2 infection regardless of symptoms, the ONS CIS gives an accurate picture of SARS-CoV-2 prevalence in the UK that is not subject to biases due to, for example, increased sampling effort in different geographical areas or demographic groups, or among symptomatic individuals [4] [5] [6] . By sequencing RT-PCR positive samples collected as part of ONS-CIS data between April 2020 and November 2021, we observed four sweeps or partial sweeps by lineages B.1.177, B.1.1.7/Alpha, B.1.617.2/Delta, and AY.4.2. This resulted in a pattern of relatively steady within-lineage evolution, followed by periodioc replacement by faster growing lineages which were characterised by a step-increase in the number of substitutions. This in turn resulted in faster overall rates of evolution when measured across all lineages, and fluctuating levels of genetic diversity. Whether this pattern will be an ongoing feature of SARS-CoV-2 evolution remains to be seen.

Of the ~1.3 million UK sequences collected during the period studied here as part of the COG-UK consortium [3] , about 1.6% were samples collected as part of the ONS CIS. The comparatively smaller sample sizes associated with the ONS-CIS makes it more difficult to identify small clusters of infection, and may delay the detection of lineages with a growth rate advantage. For example, only two B.1.258/Beta samples were identified from sequenced ONS CIS samples during February, March and April 2021, despite the occurance of a sizeable outbreak in South London during this time. Moreover, a clear increase in the proportions of B.1.177, B.1.617.2/Delta, and AY.4.2 cases was detected about two-four weeks later in the ONS CIS data compared to the whole COG-UK data. The sampling of all individuals regardless of symptoms in ONS may also generate a short lag in the detection of a growth advantage compared to COG-UK as a whole: ONS effectively measures pathogen prevalence (total number of infected individuals), whereas COG-UK data effectively measures incidence (total number of new infections).

As well as the smaller sample sizes contributing to the delayed detection of growing lineages, it is also possible that a higher proportion of COG-UK samples represented communities and/or demographics where imported cases took hold. We note that detection is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.05.21268323 doi: medRxiv preprint of B.1.1.7/Alpha, which likely emerged in the UK, was not associated with delayed detection in the ONS-CIS data. Other community surveillance sampling strategies can partially compensate for the lower number of sequenced samples on a given day by concentrating sampling over a short period of time. For example, the REACT study [10] concentrates sampling over a few days each month, which enabled characterisation of the spread of B.617.2/Delta in the UK [37]. However, this is at the cost of the temporal granularity needed to rapidly detect fast growing variants such as B.1.1.529/Omicron.

A further drawback of relying on sequening for genomic surveillance is the delay between sample collection and subsequent sequencing (the ONS CIS has lags in the data of two weeks or more) and the need for high viral loads to produce adequate sequence data. This in turn could severely impact the success of any interventions. The earliest signals that both B.1.1.7/Alpha and B.1.1.529/Omicron [38] had a growth rate advantage were serendipitously inferred from the increasing incidence of SGTF during RT-PCR testing. The introduction of qPCR-based genotyping for specific VOCs and VUIs into diagnostic pipelines has the potential to speed-up detection of known variants. However, qPCR-based genotyping cannot be relied upon to characterise emerging variants fast enough to contain them due to the lead time required to manufacture and distribute specific assays. Moreover, substantial genome sequencing efforts will always be required to detect variants that have not previously been identified as of concern, to monitor the ongoing specificity of rapid genotyping in the face of ongoing evolution, and to better characterise the evolution and spread of the virus.

Due to foresight and investment, the COG-UK consortium has now sequenced over 1.6 million RT PCR positive samples spanning the UK SARS-CoV-2 epidemic. This has enabled the detection and tracking of genomic variants in the UK [21] , quantification of their growth advantage [14] , and inference regarding patterns of spread [28, 39] . However, it is unlikely that this unprecedented sequencing effort can be sustained in the long term, and in most countries this level of sequencing has never been feasible, with patchy sequencing efforts among different countries and regions [40] . Although only a fraction of the COG-UK sequences were comprised of samples collected as part of the ONS CIS, we were able to use ONS CIS sequenced samples to monitor the emergence, spread and evolution of the major lineages and sublineages sweeping through the UK population.

Moving forwards, the implementation of genomic surveillance globally should be considered a key development goal, enabling the early detection of worrisome and/or rapidly growing lineages wherever they emerge. Community surveillance studies similar to ONS-CIS may therefore provide powerful cost-effective tools for pathogen genomic surveillance in the future, particularly if combined with the continued sequencing of a small proportion of samples from symptomatic individuals. Incorporating the detection and sequencing of other pathogens into the same community surveillance frameworks will only act to enhance the positive public health and scientific outcomes from these studies whilst maximising value for money. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.05.21268323 doi: medRxiv preprint

The ONS CIS is a UK household-based surveillance study with selected households chosen to ensure a representative sample of the population. For a full description of the sampling design see [6] , but in brief swabs were taken from individuals aged two years and older living in private households, from 26th April 2020 onwards. These households were selected randomly from address lists and previous ONS surveys to provide a representative sample of the population. Participants could provide consent for optional follow-up sampling weekly for the first five weeks, and monthly thereafter.

This work contains statistical data from ONS which is Crown Copyright. The use of the ONS statistical data in this work does not imply the endorsement of the ONS in relation to the interpretation or analysis of the statistical data. This work uses research datasets which may not exactly reproduce National Statistics aggregates.

For samples collected from 26th April 2020 to approximately mid-December 2020, a random selection were selected for sequencing. RNA extracts were amplified using the ARTIC amplicon protocol [41] and most were sequenced on Illumina Novaseq with consensus fasta sequences produced using the ARTIC nextflow processing pipeline [41] . A small number of samples (36) in our study were sequenced using Oxford Nanopore GridION or MINION. Thereafter, the ambition was to sequence all positive samples including retrospective sequencing of stored RT-PCR positive samples where available (after a couple of months it was decided to only sequence samples with Ct<30, since samples with higher Ct values had a high failure rate due to low levels of virus). The move to sequence all RT-PCR positive samples coincided with a move to veSeq, an RNASeq protocol based on a quantitative targeted enrichment strategy [42,43] and sequenced on Illumina Novaseq. Consensus sequences were produced using shiver [44] . If the same sample was sequenced twice, the consensus sequence with the lowest genome coverage was excluded from the analysis. Fig.  S6 shows the proportion of all ONS CIS RT PCR positive samples with Ct <=30, and the proportion of these samples that have sequence >50% coverage. Finally, from mid-July 2021 onwards, sequences were again sequenced using ARTIC.

We have previously shown that Log10 viral load is positively correlated with the Log10 number of mapped reads obtained using veSeq, and that Ct is negatively correlated with the Log10 number of mapped reads [42, 45] . For all samples sequenced using the veSeq protocol we compared the Log10 mapped reads with Ct, obtaining a strong negative correlation [ Fig. S7 ]. Outliers may have a number of different causes including PCR amplification or sequence failures. Samples from individual sequencing plates where no clear correlation was observed were excluded from all analyses. All remaining sequences with coverage >=50% were included. In total, 10,042 ARTIC/Illumina, 36 ARTIC/Nanopore, and 6775 veSeq/Illumina sequences were included.

Lineage calling Lineages using the Pango nomenclature [22] were determined using the Pangolin software [23] . Reported lineages include any sub-lineages, except where stated otherwise. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. Lineage growth rates and doubling times For each of the three most common lineages observed in our dataset, B.1.177, B.1.1.7/Alpha, and B.1.617.2/Delta, we calculated their relative growth rate advantage compared to all other lineages in our data using a generalised smoothing method.

Suppose we have two species with exponential growth rates ! and " and therefore expected counts

respectively. Then the probability of a uniform random sample from both being of type 1 is

We now consider the log odds, ( ) of being type 1 over time; using the standard definition of these we obtain

Therefore, if we take the derivative of this quantity, we obtain the relative growth rate advantage for species 1 and associated doubling time,

This doubling time when calculated gives the time for ! / " to double if the current trends continue.

In practice, we do not measure ( ) directly, but rather work with a sample, with being a vector of times that samples are taken and being an associated vector with values equal to 0 if species 2 is observed and 1 if species 1 is observed. Because we wish to differentiate the time trend, traditional splines that have penalised or zero derivatives may not be appropriate, and so we place a Gaussian process prior on with the Radial Basis Function (RBF) kernel, which has & samples (i.e., all derivatives exist).

To implement this we can use the approach from is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.05.21268323 doi: medRxiv preprint relative growth advantage, and so bootstrap the data vectors and , then use the kernel hyperparameters optimised on real data to produce an ensemble of bootstrapped curves for ( ). For the original data and bootstrapped curves, we can then also produce estimates of growth advantage from the equations above.

The alignment of consensus sequences with at least 95% coverage was used for phylogenetic reconstruction using RAxML-NG version 0.9.0 [47]. The resulting tree was rooted and fit to calendar time using TreeTime version 0.8.2 [35] . Ancestral sequence reconstruction was performed on the TreeTime divergence tree using IQ-TREE version 1.6.12 [48] . Visualisation used ggtree [49] .

Nucleotide genetic diversity We calculated the genetic diversity among consensus sequences for all sequenced samples collected in a particular week and with >50% coverage. Nucleotide genetic diversity was calculated using the π statistic, since this has been shown to be the least sensitive to differences in the number of sequences used in the analysis [50] . Mean pairwise genetic diversity across the genome is given by:

Where represents the length of the genome, and ) the pairwise genetic diversity at locus . This is calculated as:

Where ) represents the number of alleles observed at that locus, and the number of samples with a consensus base call.

Within-lineage genetic diversity was calculated as above, but limiting only to sequences identified as belonging to B. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.05.21268323 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.05.21268323 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.05.21268323 doi: medRxiv preprint Figure S4 . Divergence by lineage for all samples with over 95% genome coverage. A maximum likelihood phylogeny of ONS sequences with over 95% genome coverage up to and including 13th November 2021 (Fig S3) was generated using RAxML-NG, from which root-to-tip distances were calculated. Regressions were performed separately for B. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.05.21268323 doi: medRxiv preprint Figure S5 . Mutations in Spike conferring antigenic change for the three most common lineages. The stacked bar chart indicates the number of samples in our dataset with the mutation, up until 17th July 2021. All antigenic mutations included in the COG-UK mutational explorer [19] , were included. For clarity, mutations on a lineage that define that lineage are not considered. Numbers above the bars indicated the number of ancestral nucleotide changes on the phylogeny of all ONS CIS sequences with >95% coverage, if greater than one, whereas numbers superimposed onto the bars indicate the number of ancestral nodes associated with that lineage. The y-axis has been truncated at 26 for clarity, but up until 17th July 2021 L18F was observed in 76 Alpha samples, and was associated with 14 ancestral nucleotide changes. Apparent discrepancies occur because samples with <95% coverage were not included in the phylogeny (hence e.g. L455F only has one ancestral node on the phylogeny yet appears on both B. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.05.21268323 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted January 6, 2022. ; https://doi.org/10.1101/2022.01.05.21268323 doi: medRxiv preprint

WHO. Tracking SARS-CoV-2 variants

SARS-CoV-2 variants, spike mutations and immune escape

The COVID-19 Genomics UK (COG-UK) consortium. An integrated national scale SARS-CoV-2 genomic surveillance network. The Lancet Microbe

Population-based prevalence surveys during the Covid-19 pandemic: A systematic review

Reconstruction and prediction of viral disease epidemics

Community prevalence of SARS-CoV-2 in England from

Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis

TaqPath Polymerase Chain Reaction

Increased infections, but not viral burden, with a new SARS-CoV-2 variant

Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7

Variants of Concern Technical Briefing 10

Coronavirus (COVID-19) Infection Survey, UK -Office for National Statistics

Variants: distribution of case data

Monitoring populations at increased risk for SARS-CoV-2 infection in the community

Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool

Coronavirus (COVID-19) Infection Survey: technical data -Office for National Statistics

Spread of a SARS-CoV-2 variant through Europe in the summer of 2020

Genomic reconstruction of the SARS-CoV-2 epidemic in England

Spatiotemporal invasion dynamics of SARS-CoV-2 lineage B.1.1.7 emergence

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Estimating infectiousness throughout SARS-CoV-2 infection course

Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study

SARS-CoV-2 variants of concern and variants under investigation in England Technical briefing 27

Coronavirus (COVID-19) Infection Survey, UK -Office for National Statistics

Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

TreeTime: Maximum-likelihood phylodynamic analysis

Variants of Concern Technical Briefing 6

Samples and logistics, and Software and analysis tools: Dr Igor Starinskij MSc

Olivia Boyd MSc 39 , Lily Geidelberg MSc 39

Software and analysis tools, and Visualisation

Dr Beatrice Bertolusso Degree 33 , Dr Jessica Lynch MBCHB 33

Karlie Fallon 16 , Thomas Helmer 16 , Dr Claire L McMurray PhD 16 , Mina Odedra BSc 16

Dr Sarah Wyllie PhD 68 , Richard Hopes 70 , Dr Chloe Bishop PhD 72 , Dr Vicki Chalker PhD 72 , Dr Ian Harrison PhD 72 , Laura Gifford MSc 74 , Dr Zoltan Molnar PhD 77 , Dr Cressida Auckland FRCPath 79 , Dr Cariad Evans PhD 85

Dr David Lee PhD 72 , Nikos Manesis 72 , Dr Tamyo Mbisa PhD 72 , Dr Steven Platt PhD 72 , Katherine A Twohig 72 , Dr Mari Morgan PhD 74